An Open-Label Study to Evaluate the Efficacy and Safety of a Single-Dose of Oral CEM-101 in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea

Trial Profile

An Open-Label Study to Evaluate the Efficacy and Safety of a Single-Dose of Oral CEM-101 in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Solithromycin (Primary)
  • Indications Gonorrhoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2013 Results were presented in April 2013 at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) according to a Cempra media release.
    • 26 Apr 2013 Results will be presented at the 2013 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) according to a Cempra media release. Results were also summarised in the media release.
    • 22 Oct 2012 Planned number of patients changed from 30 to 55.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top